DEXA Body Composition: Medication-Driven Changes, Normal Ranges, and Optimal Targets

What DEXA Actually Measures in a Body Composition Scan

DEXA body composition scanning uses two X-ray beams at different energy levels to distinguish bone mineral, lean soft tissue, and fat tissue across the whole body and regional segments. The scan takes 6 to 10 minutes, delivers 1 to 6 µSv of ionizing radiation, and produces four clinically actionable outputs: total fat mass (kg and percent), total lean mass (kg), bone mineral density (g/cm²), and visceral adipose tissue (VAT) mass or area.

The Four Primary Outputs

Fat mass and fat percent. The scanner reports absolute fat mass in kilograms and as a percentage of total body weight. Regional breakdowns, android (trunk), gynoid (hip/thigh), and appendicular, allow clinicians to distinguish metabolically dangerous central adiposity from less harmful peripheral fat [1].

Lean mass. Lean soft tissue includes skeletal muscle, organ tissue, and connective tissue. Appendicular lean mass (ALM), the sum of arm and leg lean mass, is the most clinically validated proxy for skeletal muscle mass. The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project defined low ALM as <19.75 kg in men and <15.02 kg in women based on DEXA data from five large cohorts (N=26,625) [2].

Bone mineral density. Reported as grams per cm², compared against a young-adult reference (T-score) and an age-matched reference (Z-score). WHO criteria define osteopenia at a T-score of -1.0 to -2.5 and osteoporosis below -2.5 [3].

Visceral adipose tissue. VAT is the metabolically active fat surrounding abdominal organs. The American Association of Clinical Endocrinology (AACE) considers VAT area above 100 cm² a threshold associated with increased cardiometabolic risk [4]. Most modern DEXA software (GE Lunar, Hologic Horizon) estimates VAT mass directly from the android region using a validated algorithm.

Why Segmental Analysis Matters

Whole-body fat percent alone can be misleading. A patient may have an acceptable total body fat percentage yet carry pathological amounts of visceral fat. Segmental analysis showing an android-to-gynoid fat ratio above 1.0 predicts cardiovascular risk independently of BMI, as demonstrated in the Multi-Ethnic Study of Atherosclerosis (MESA), where each standard-deviation increase in VAT area was associated with a 1.44-fold increase in incident cardiovascular events (N=6,814) [5].

Normal Ranges for DEXA Body Composition by Sex and Age

Reference ranges come primarily from NHANES III DEXA sub-studies and the GE Lunar / Hologic normative databases, which together cover thousands of American adults. Ranges shift with age because lean mass declines roughly 1 to 2% per year after age 50 and fat mass typically rises even when scale weight is stable [6].

Body Fat Percentage Reference Values

| Age group | Men (normal) | Women (normal) | Men (obesity threshold) | Women (obesity threshold) | |---|---|---|---|---| | 20 to 39 y | 8 to 20% | 21 to 33% | >25% | >39% | | 40 to 59 y | 11 to 22% | 23 to 35% | >28% | >40% | | 60+ y | 13 to 25% | 24 to 36% | >30% | >42% |

These thresholds are drawn from the Gallagher et al. Percent body fat reference ranges published in the American Journal of Clinical Nutrition using DEXA data from a four-country cohort (N=1,626) [7].

Appendicular Lean Mass Index Cutoffs

ALM index (ALMI) normalizes appendicular lean mass to height squared (kg/m²). The FNIH Sarcopenia Project reported that ALMI below 0.789 in men and below 0.512 in women (as a ratio to BMI) was associated with weakness and slow gait speed in adults 65 and older [2]. In younger adults on anabolic or catabolic therapies, serial ALMI is the most sensitive marker of meaningful muscle change.

Optimal DEXA Body Composition Targets

"Normal" is not the same as optimal. Longevity research consistently shows that the lower end of normal fat mass combined with above-average lean mass associates with the best survival outcomes, independent of body weight.

Optimal Fat Mass

A 2021 analysis in the European Heart Journal (N=22,925 follow-up over 11.8 years) found that cardiovascular mortality was lowest in men with body fat 15 to 20% and women with body fat 25 to 30% by DEXA, with U-shaped curves showing excess risk below 10% (men) and above 38% (women) [8]. For patients on GLP-1 therapy aiming to reduce cardiometabolic risk, a practical clinical target is body fat <25% in men and <33% in women while preserving ALMI above the FNIH cutoffs.

Optimal Lean Mass

No absolute lean mass target applies universally, but the BLSA (Baltimore Longitudinal Study of Aging) data show that men in the top quartile of ALMI at age 60 had a 2.1-fold lower all-cause mortality hazard over 20 years compared with the lowest quartile [9]. Preserving or increasing ALMI should be an explicit treatment goal whenever a medication is expected to change body weight significantly.

Optimal Visceral Adipose Tissue

VAT below 100 cm² (roughly 0.5 to 1.0 kg VAT mass on Hologic Horizon software) is associated with normal cardiometabolic risk in most published cohorts [4]. VAT above 160 cm² carries a substantially elevated risk of type 2 diabetes, hypertension, and non-alcoholic fatty liver disease [5].

HealthRX Clinical Target Framework for Patients on Body-Recomposition Therapy:

1. Body fat percent: reach sex- and age-appropriate lower-normal range (men <22%, women <33% for ages 40 to 59).
2. ALMI: maintain at or above FNIH median for age and sex throughout therapy.
3. VAT mass: drive below 1.0 kg (Hologic) or VAT area below 100 cm².
4. Fat-free mass index (FFMI): men target FFMI 18 to 22 kg/m²; women target FFMI 14 to 17 kg/m².
5. Android/gynoid ratio: target below 0.9 in women, below 1.1 in men.

This five-metric framework allows the HealthRX clinical team to flag patients who are losing disproportionate lean mass or failing to reduce visceral fat despite overall weight loss.

How GLP-1 Receptor Agonists Change Body Composition on DEXA

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce substantial weight loss, but the composition of that lost weight matters clinically. DEXA data from the major outcome trials show that a meaningful fraction of the weight lost comes from lean tissue, not fat.

Semaglutide 2.4 mg (Wegovy): STEP-1 DEXA Substudy

The STEP-1 trial (N=1,961) assigned adults with obesity to semaglutide 2.4 mg subcutaneous weekly or placebo for 68 weeks. Mean total weight loss in the semaglutide group was 14.9% vs. 2.4% in the placebo group (P<0.001) [10]. In the DEXA substudy (N=140), approximately 39% of the weight lost in the semaglutide group was lean mass. Fat mass fell by 10.2 kg, while lean mass fell by 5.3 kg, a lean-mass loss ratio considered clinically significant by most geriatric medicine consensus panels [11].

Tirzepatide (Mounjaro/Zepbound): SURMOUNT-1 Body Composition Data

The SURMOUNT-1 trial (N=2,539) demonstrated 20.9% mean weight loss with tirzepatide 15 mg at 72 weeks vs. 3.1% with placebo [12]. DEXA sub-analyses showed that roughly 25 to 33% of weight lost was lean tissue, a somewhat better lean-mass preservation ratio than seen with semaglutide monotherapy, possibly due to tirzepatide's dual GIP/GLP-1 activity affecting muscle protein synthesis pathways. These sub-analyses have not yet been published in full peer-reviewed form, so the ratio should be treated as preliminary [12].

Liraglutide 3.0 mg (Saxenda): Older DEXA Data

The SCALE Obesity and Prediabetes trial (N=3,731) showed 8.4% weight loss with liraglutide 3.0 mg over 56 weeks [13]. A separate DEXA analysis in a smaller subset found that lean mass constituted roughly 22 to 28% of total weight lost. Liraglutide produces less overall weight loss than semaglutide, so absolute lean-mass losses are smaller, but the proportional lean-tissue loss is similar [13].

Clinical Implication: Concurrent Resistance Training

The 2023 American College of Sports Medicine position stand on exercise and GLP-1 therapy recommends progressive resistance training 2 to 3 times per week to attenuate lean-mass loss during GLP-1-induced weight loss [14]. DEXA is the recommended monitoring tool to confirm lean-mass preservation at each training program review. A reasonable monitoring interval is every 12 to 16 weeks during active dose titration.

How Testosterone Replacement Therapy Changes DEXA Results

Testosterone replacement therapy (TRT) shifts body composition in a predictable direction detectable on DEXA: lean mass rises, fat mass falls, and bone mineral density often improves over 12 to 24 months of therapy.

Effect Size from Meta-Analysis

A 2016 systematic review and meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=1,083, 26 RCTs) found that TRT increased lean mass by a weighted mean of 1.6 kg (95% CI 0.9 to 2.3 kg) and decreased fat mass by 1.5 kg (95% CI 0.7 to 2.2 kg) vs. Placebo at 12 to 24 months [15]. Effects were larger in men with baseline testosterone below 300 ng/dL and in men who combined TRT with resistance training.

Timeline of Changes on DEXA

Lean mass gains from TRT are detectable on DEXA as early as 12 weeks, with most of the measurable change occurring between weeks 12 and 52. Fat mass reductions tend to follow lean mass increases, becoming statistically significant by month 6 in most published trials [15]. Bone mineral density changes are slower: clinically meaningful increases typically require 12 to 24 months of therapy [16].

Monitoring Protocol on TRT

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends baseline DEXA for bone mineral density in men with hypogonadism and osteoporosis risk factors, with repeat scanning at 1 to 2 years [16]. For body composition tracking specifically, HealthRX protocols add a DEXA at 12 weeks (to confirm anabolic response), 6 months, and 12 months. The minimum meaningful change threshold is approximately 500 g for lean mass and 400 g for fat mass on fan-beam DEXA.

How Other Medications Affect DEXA Body Composition

GLP-1s and TRT are not the only therapies that produce measurable DEXA changes. Several medications used in hormonal and metabolic medicine shift body composition in ways that DEXA can detect within 3 to 6 months.

Aromatase Inhibitors (Anastrozole, Letrozole)

Aromatase inhibitors reduce estrogen in both women (breast cancer adjuvant therapy) and men (hypogonadism with high estradiol). In women, a 2020 Cochrane review of adjuvant aromatase inhibitor therapy found significant lean mass loss (-0.9 to -1.4 kg) and fat mass gain (+0.8 to +1.1 kg) at 24 months compared with baseline, with accompanying bone mineral density losses at the lumbar spine [17]. DEXA monitoring every 12 months is standard practice in oncology settings and should be applied in hormone therapy settings as well.

Androgen Deprivation Therapy (Leuprolide, Degarelix)

Androgen deprivation therapy (ADT) for prostate cancer produces the most dramatic medication-driven body composition changes quantifiable on DEXA. A meta-analysis in the Journal of Urology (N=4,704) reported lean mass loss of 2.7 kg and fat mass gain of 3.2 kg after 12 months of ADT [18]. The clinical consequence is sarcopenic obesity, simultaneously low lean mass and high fat mass, which increases fall risk, fracture risk, and cardiovascular mortality. DEXA every 6 to 12 months is recommended in this population.

Glucocorticoids (Prednisone, Dexamethasone)

Chronic glucocorticoid use (prednisone 5 mg/day for 6 months or longer) predictably causes muscle atrophy measurable on DEXA. The ACR guidelines on glucocorticoid-induced osteoporosis recommend baseline DEXA before starting therapy anticipated to last 3 months or longer, with follow-up at 12 months [19].

How to Read Your DEXA Report: Key Numbers to Extract

Most DEXA software (GE Lunar iDXA, Hologic Horizon) produces a multi-page report. Patients and clinicians should focus on six specific values.

Six Numbers That Matter

1. Total body fat percent, compare against the Gallagher age- and sex-specific reference ranges [7].
2. Android fat percent, values above 35% in men or 45% in women indicate central obesity risk even with acceptable total fat.
3. Visceral adipose tissue mass (kg) or VAT area (cm²), target below 1.0 kg / 100 cm².
4. Appendicular lean mass index (ALMI, kg/m²), compare against FNIH cutoffs; decline greater than 3% between scans warrants clinical review [2].
5. Lean mass change from prior scan (kg), subtract prior scan value; a loss greater than 500 g over 12 to 16 weeks on GLP-1 therapy without resistance training is a trigger for protocol adjustment.
6. Lumbar spine T-score, particularly relevant on aromatase inhibitor or ADT therapy; T-score below -1.5 warrants pharmacological bone protection discussion.

Scan Methodology: What Affects DEXA Accuracy

DEXA results can vary meaningfully across scanner models, software versions, and scan conditions. Understanding these sources of variability is necessary for interpreting serial scans correctly.

Sources of Variability

Machine differences. GE Lunar and Hologic scanners use different algorithms and produce systematically different absolute values for fat mass and lean mass. A patient scanned on a GE Lunar in January and a Hologic in April cannot make a valid comparison. Serial scans should be done on the same machine, preferably with the same software version [20].

Hydration status. A 2 kg difference in body water shifts the lean mass reading by approximately 1.5 to 2.0 kg on DEXA because water distributes into the lean-tissue compartment. Patients should be in a consistent hydration state (no heavy exercise, no alcohol, normal fluid intake) before each scan [20].

Clothing and metal. Metal objects cause artifact. Patients should wear minimal clothing without metal fasteners and remove all jewelry. Some underwire bras add 200 to 400 g to apparent trunk fat readings.

Time of day and meal timing. Gastrointestinal content contributes to apparent trunk fat readings. A 12-hour fast before scanning is recommended for maximal consistency, though many commercial facilities do not enforce this requirement.

How Often to Repeat DEXA on Hormone or GLP-1 Therapy

Scan frequency should match the expected rate of change and the clinical decision points in the treatment protocol.

Recommended Monitoring Intervals

For patients on GLP-1 receptor agonists (semaglutide, tirzepatide): baseline before starting, then every 12 to 16 weeks during active dose titration, then every 6 months during maintenance. This interval captures the lean-mass trajectory early enough to intervene with resistance training or protein supplementation before sarcopenia develops [11].

For patients on TRT: baseline before starting (or within 4 weeks of first injection/gel application), then at 12 weeks, 6 months, and 12 months. After 12 months of stable therapy, annual scans are sufficient unless the dose changes [16].

For patients on ADT or aromatase inhibitors: baseline, then every 6 to 12 months, with particular attention to bone mineral density as well as body composition [17, 18].

For patients not on active therapy who are tracking aging-related body composition changes: every 12 to 24 months is sufficient in most cases.

Interpreting Medication-Driven Changes: A Clinical Decision Framework

Not every lean-mass loss on a serial DEXA scan requires a protocol change. The clinical decision depends on the absolute amount lost, the fat-to-lean loss ratio, the patient's baseline ALMI, and functional status.

When to Act

A lean-mass loss greater than 3% of baseline ALMI over 12 to 16 weeks on GLP-1 therapy is a signal for structured resistance training prescription and protein intake optimization (minimum 1.6 g/kg body weight per day, per the International Society of Sports Nutrition position stand) [21].

A DEXA scan showing VAT area above 160 cm² despite 10% body weight loss on GLP-1 therapy suggests that visceral fat is resistant to the current approach, and adding caloric restriction or physical activity may be needed beyond pharmacotherapy alone [5].

A DEXA scan showing no lean mass gain after 6 months of TRT suggests either subtherapeutic testosterone levels, poor protocol adherence, insufficient dietary protein, or concurrent catabolic medication. The response should be to check trough testosterone, review diet, and assess for concurrent medications affecting muscle anabolism [15].